Soverini S, Bassan R, Lion T. Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. J Hematol Oncol. 2019;12:39.

Article  PubMed  PubMed Central  Google Scholar 

Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, et al. Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2020;18:1385–415.

Article  CAS  Google Scholar 

Osman AEG, Deininger MW. Chronic myeloid leukemia: modern therapies, current challenges and future directions. Blood Rev. 2021;49: 100825.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou H, Xu R. Leukemia stem cells: the root of chronic myeloid leukemia. Protein Cell. 2015;6:403–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

García-Gutiérrez V, Breccia M, Jabbour E, Mauro M, Cortes JE. A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase. J Hematol Oncol. 2022;15:90.

Article  PubMed  PubMed Central  Google Scholar 

Braun TP, Eide CA, Druker BJ. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell. 2020;37:530.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheloni G, Tanturli M, Tusa I, Ho DeSouza N, Shan Y, Gozzini A, et al. Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine. Blood. 2017;130:655–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol. 2022;15:113.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17.

Article  CAS  PubMed  Google Scholar 

Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saglio G, Kim D-W, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251–9.

Article  CAS  PubMed  Google Scholar 

Cortes J, Lang F. Third-line therapy for chronic myeloid leukemia: current status and future directions. J Hematol Oncol. 2021;14:44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31:2398–406.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saußele S, Krauß M-P, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood. 2015;126:42–9.

Article  PubMed  PubMed Central  Google Scholar 

Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goyne JM, Slader C, Filshie RJ, Mills AK. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515–22.

Article  CAS  PubMed  Google Scholar 

Hattori A, Tsunoda M, Konuma T, Kobayashi M, Nagy T, Glushka J, et al. Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia. Nature. 2017;545:500–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peters JM, Shah YM, Gonzalez FJ. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer. 2012;12:181–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Augimeri G, Gelsomino L, Plastina P, Giordano C, Barone I, Catalano S, et al. Natural and synthetic PPARγ ligands in tumor microenvironment: a new potential strategy against breast cancer. Int J Mol Sci. 2020;21:9721.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mason EF, Zhao Y, Goraksha-Hicks P, Coloff JL, Gannon H, Jones SN, et al. Aerobic glycolysis suppresses p53 activity to provide selective protection from apoptosis upon loss of growth signals or inhibition of BCR-Abl. Cancer Res. 2010;70:8066–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shinohara H, Taniguchi K, Kumazaki M, Yamada N, Ito Y, Otsuki Y, et al. Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia. Cancer Lett. 2015;360:28–38.

Article  CAS  PubMed  Google Scholar 

Zuo Q, He J, Zhang S, Wang H, Jin G, Jin H, et al. PPARγ coactivator-1α suppresses metastasis of hepatocellular carcinoma by inhibiting warburg effect by PPARγ-dependent WNT/β-catenin/pyruvate dehydrogenase kinase isozyme 1 axis. Hepatology. 2021;73:644–60.

Article  CAS  PubMed  Google Scholar 

Youssef J, Badr M. Peroxisome proliferator-activated receptors and cancer: challenges and opportunities. Br J Pharmacol. 2011;164:68–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ryu S, Kim DS, Lee MW, Lee JW, Sung KW, Koo HH, et al. Anti-leukemic effects of PPARγ ligands. Cancer Lett. 2018;418:10–9.

Article  CAS  PubMed  Google Scholar 

Prost S, Relouzat F, Spentchian M, Ouzegdouh Y, Saliba J, Massonnet G, et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists. Nature. 2015;525:380–3.

Article  CAS  PubMed  Google Scholar 

Rousselot P, Prost S, Guilhot J, Roy L, Etienne G, Legros L, et al. Pioglitazone together with imatinib in chronic myeloid leukemia: a proof of concept study. Cancer. 2017;123:1791–9.

Article  CAS  PubMed  Google Scholar 

Zhou H, Jiang Y, Huang Y, Zhong M, Qin D, Xie C, et al. Therapeutic inhibition of PPARα-HIF1α-PGK1 signaling targets leukemia stem and progenitor cells in acute myeloid leukemia. Cancer Lett. 2023;554: 215997.

Article  CAS  PubMed  Google Scholar 

Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol. 2019;37:907–15.

Article  CAS  PubMed  PubMed Central  Google Scholar